Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2019
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA StudyEmmanuel Bachy, John F Seymour, Pierre Feugier, et al.
Blood|November 9, 2020
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Blood Advances|April 7, 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
The Lancet. Haematology|July 21, 2019
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trialAnne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, et al.
The New England Journal of Medicine|September 6, 2018
Rituximab plus Lenalidomide in Advanced Untreated Follicular LymphomaFranck Morschhauser, Nathan H Fowler, Pierre Feugier, et al.
Haematologica|September 2, 2018
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphomaRémy Gressin, Nicolas Daguindau, Adrian Tempescul, et al.
Haematologica|November 30, 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA groupSylvain Carras, Alexia Torroja, Anouk Emadali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R<sup>2</sup>) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular LymphomaFranck Morschhauser, Loretta Nastoupil, Pierre Feugier, et al.
Blood Advances|August 4, 2025
Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II StudyOlivier Tournilhac, Krimo Bouabdallah, Solene Lecolant, et al.
Blood|March 31, 2026
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysisNicolas Gower, Pierre Feugier, Jason R Westin, et al.
Pageof 7